The Effect of Nasal Hair on Nasal Obstruction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01850511|
Recruitment Status : Completed
First Posted : May 9, 2013
Last Update Posted : January 22, 2014
|Condition or disease||Intervention/treatment||Phase|
|Nasal Obstruction||Procedure: Vibrissae trimming Drug: Application of oxymetazoline||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of Vibrissae on Subjective and Objective Measures of Nasal Obstruction|
|Study Start Date :||May 2013|
|Actual Primary Completion Date :||October 2013|
|Actual Study Completion Date :||October 2013|
Experimental: Vibrissae trimming
Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.
Procedure: Vibrissae trimming
Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
Drug: Application of oxymetazoline
Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
Other Name: Afrin
- Nasal airflow/pressure [ Time Frame: Participants will undergo assessment over a 30 minute period, no follow-up ]Objective measures include airflow and pressure as assessed by Rhinomanometry.
- Subjective Nasal Obstruction [ Time Frame: Participants will undergo assessment over a 30 minute period, no follow-up ]Subjective measures will be assessed via the modified version of the NOSE outcome instrument-a validated test of subjective nasal obstruction
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01850511
|United States, Minnesota|
|Mayo Clinic in Rochester|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Grant Hamilton, MD||Mayo Clinic|